Penn Medicine The 7th Alfred P. Fishman Symposium New Scientific Discoveries and Impact on Patients with Pulmonary Hypertension or Pulmonary Embolism 2025

 Include: 18 videos + 17 pdfs, size: 6.83 GB

Target Audience: internists, pulmonologists, cardiologists, critical care physicians

Information:

The Alfred P. Fishman Symposium will present cutting-edge topics pertinent to various types of pulmonary vascular disease. Major advances in research and understanding of the pathobiology and physiology in different types of pulmonary hypertension have translated into novel treatments for patients and a new way of looking at what constitutes successful treatment. Evolving treatment paradigms require a re-evaluation of clinical trial designs which are focused on patient well-being.

1. Review how recent scientific discoveries in pulmonary hypertension can directly translate to improved patient outcomes
2. Discuss the different types of pulmonary hypertension and the appropriate treatment for each.
3. Describe the approach to risk stratification and choice of therapies or referral for lung transplantation
4. Review the new standard of care in treatment of pulmonary embolism and follow-up
5. Discuss novel and alternative approaches to studying treatments in patients with pulmonary hypertension

The 7th Alfred P. Fishman Symposium: New Scientific Discoveries and Impact on Patients with Pulmonary Hypertension or Pulmonary Embolism (2025) is designed for physicians and healthcare professionals specializing in pulmonary vascular diseases.

This symposium is particularly beneficial for:

• Internal Medicine Physicians managing pulmonary hypertension and embolism.
• Pulmonologists & Pediatric Pulmonologists focusing on advanced treatment strategies.
• Cardiologists involved in cardiovascular aspects of pulmonary vascular disease.
• Critical Care Physicians overseeing high-risk pulmonary cases.
• Researchers & Clinicians interested in novel therapies and evolving treatment paradigms.

The event will cover cutting-edge research, risk stratification, treatment approaches, and emerging therapies for pulmonary hypertension and embolism.

 Topics:

• BPA.mp4
  BPA.pdf
  Comorbidities, Inclusion Criteria, and Treatment Effects – More or Less.pdf
  Connect the Tissue Disease Dots in Pulmonary Hypertension.mp4
  Connect the Tissue Disease Dots in Pulmonary Hypertension.pdf
  Data Safety and Monitoring in PAH.mp4
  Data Safety and Monitoring in PAH.pdf
  Hospitalized patient with PAH or IPAH- The Lung Phenotype.mp4
  Hospitalized patient with PAH or IPAH- The Lung Phenotype.pdf
  Magic 8-Ball Says the Patient Has HFpEF PH.mp4
  Magic 8-Ball Says the Patient Has HFpEF PH.pdf
  Minimizing Health Care-Research Contact Days- No place like home.mp4
  Minimizing Health Care-Research Contact Days- No place like home.pdf
  PE(nn) Wars- Debate.mp4
  PE(nn) Wars- Debate.pdf
  People Living with Pulmonary Arterial Hypertension – In Their Own Words.mp4
  Recruiting Minority Members into PH Clinical Trials-Why and how-.mp4
  Recruiting Minority Members into PH Clinical Trials-Why and how-.pdf
  Sex Healing in PAH.mp4
  Sex Healing in PAH.pdf
  Slow Metabolism- The Right Ventricle in Pulmonary Hypertension.mp4
  Slow Metabolism- The Right Ventricle in Pulmonary Hypertension.pdf
  Talking to People who (may) Have a New Diagnosis of Pulmonary Hypertension.mp4
  Talking to People who (may) Have a New Diagnosis of Pulmonary Hypertension.pdf
  The Science Leading to Sotatercept and Beyond.mp4
  The Science Leading to Sotatercept and Beyond.pdf
  To Transplant, or not to Transplant.mp4
  To Transplant, or not to Transplant.pdf
  Treatment of ILD-PH – When to Hold `em and When to Fold `em.mp4
  Treatment of ILD-PH – When to Hold `em and When to Fold `em.pdf
  Welcome & Introduction.mp4
  What’s the (End) Point-.mp4
  What’s the (End) Point-.pdf
  WSPH Treatment Algo in Pulmonary Hypertension.mp4
  WSPH Treatment Algo in Pulmonary Hypertension.pdf